HOUSTON--(BUSINESS WIRE)--Pharm-Olam International Ltd., a multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the appointment of Dr. Dhiraj Abhyankar to the position of Director, Scientific Development.
Dr. Abhyankar is a Medical Oncologist with over 15 years of experience at both pharmaceutical and clinical research organizations. In his prior positions he was responsible for clinical research on complex drugs, novel technology, 505B2 opportunities mainly in oncology but also across a number of other therapeutics areas including respiratory, endocrinology and CNS. His past experience also includes heading the team which conducted a clinical trial on the first global biosimilar monoclonal antibody and he has more than 25 scientific papers to his credit.
“Dr. Abhyankar’s education and experience is a valuable addition to the Pharm-Olam team,” said Sanjiv Suri, Pharm-Olam’s Chief Executive Officer. Suri added, “Dr. Abhyankar has over a decade of experience in the development of oncology therapies in all phases of the development process. In his new role, he will play a critical part in providing strategic guidance for our clients’ early phase research, and provide medical support as treatments move through the development process. With oncology trials now comprising 25% of our total trial portfolio, the addition of Dr. Abhyankar comes at an important time.”
Pharm-Olam operates in more than 60 countries worldwide, offering end-to-end clinical trial support for Phase I-IV clinical trials. More information about Pharm-Olam and its full-service capabilities and offerings is available at www.pharm-olam.com.
About Pharm-Olam International Group
Pharm-Olam International is a multinational Contract Research Organization (CRO) offering comprehensive clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines, making clinical research as Easy As I, II, III, IV™. For further information about Pharm-Olam, please visit www.pharm-olam.com.
